FGFR2IIIB is an important signal transduction receptor that plays an important role in the regulation of cell proliferation, differentiation, migration and apoptosis, as well as in the regulation of embryonic development. In normal tissues, FGFR2IIIB expression supports a variety of physiological processes, including embryonic development and tissue repair. However, dysregulation of FGFR2IIIB expression has been found in a variety of cancers. Amplification, mutation, or overexpression of FGFR2IIIB has been identified in a variety of malignancies, including breast, stomach, and lung cancers. Alterations in FGFR2IIIB expression are often associated with enhanced tumor proliferation and poor prognosis. FGFR2IIIB targets may serve as a predictor of tumor efficacy in the clinic.